Chinese biotechnology company DualityBio (HKEX:9606) announced on Monday that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310.
This designation is for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) with an EGFR exon 19 deletion or L858R mutation with disease progression on or after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.
DB-1310 is a novel ADC targeting HER3 developed using DualityBio's proprietary DITAC platform. First-in-human Phase I/IIa clinical trial data of DB-1310 demonstrated encouraging efficacy and a manageable safety profile in patients with advanced solid tumours who had failed standard therapies.
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
HotSpot Therapeutics presents small molecule CBM signalosome inhibitor program data
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Merck reports positive Phase 3 results for WINREVAIR in pulmonary arterial hypertension
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study